MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Low-grade serous ovarian carcinomas (LGSOCs) have historically low chemotherapy responses. Alterations affecting the MAPK pathway, most commonly KRAS/BRAF, are present in 30%-60% of LGSOCs. The purpose of this study was to evaluate binimetinib, a potent MEK1/2 inhibitor with demonstrated activity ac...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 38; číslo 32; s. 3753
Hlavní autoři:	Monk, Bradley J, Grisham, Rachel N, Banerjee, Susana, Kalbacher, Elsa, Mirza, Mansoor Raza, Romero, Ignacio, Vuylsteke, Peter, Coleman, Robert L, Hilpert, Felix, Oza, Amit M, Westermann, Anneke, Oehler, Martin K, Pignata, Sandro, Aghajanian, Carol, Colombo, Nicoletta, Drill, Esther, Cibula, David, Moore, Kathleen N, Christy-Bittel, Janna, Del Campo, Josep M, Berger, Regina, Marth, Christian, Sehouli, Jalid, O'Malley, David M, Churruca, Cristina, Boyd, Adam P, Kristensen, Gunnar, Clamp, Andrew, Ray-Coquard, Isabelle, Vergote, Ignace
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 10.11.2020
Témata:	Adult Aged Benzimidazoles - adverse effects Benzimidazoles - therapeutic use Cystadenocarcinoma, Serous - drug therapy Cystadenocarcinoma, Serous - enzymology Cystadenocarcinoma, Serous - pathology Doxorubicin - analogs & derivatives Doxorubicin - therapeutic use Fallopian Tube Neoplasms - drug therapy Fallopian Tube Neoplasms - enzymology Fallopian Tube Neoplasms - pathology Female Humans MAP Kinase Kinase 1 - antagonists & inhibitors MAP Kinase Kinase 2 - antagonists & inhibitors Middle Aged Neoplasm Grading Neoplasm Recurrence, Local - drug therapy Ovarian Neoplasms - drug therapy Ovarian Neoplasms - enzymology Ovarian Neoplasms - pathology Paclitaxel - therapeutic use Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - enzymology Peritoneal Neoplasms - pathology Polyethylene Glycols - therapeutic use Progression-Free Survival Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Topotecan - therapeutic use Young Adult
ISSN:	1527-7755, 1527-7755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!